Rhenman & Partners Asset Management Ab Immuno Gen, Inc. Transaction History

Rhenman & Partners Asset Management Ab

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$14.09 - $19.87 $7.35 Million - $10.4 Million	521,716 Added 292.63%	700,000 $11.1 Million
Q3 2023 Nov 09, 2023	SELL	$14.09 - $19.87 $8.06 Million - $11.4 Million	-571,716 Reduced 76.23%	178,284 $2.83 Million
Q2 2023 Aug 11, 2023	SELL	$3.75 - $20.05 $1.88 Million - $10 Million	-500,000 Reduced 40.0%	750,000 $14.2 Million
Q1 2023 May 11, 2023	SELL	$3.67 - $4.92 $917,500 - $1.23 Million	-250,000 Reduced 16.67%	1,250,000 $4.8 Million
Q4 2022 Feb 13, 2023	BUY	$4.55 - $6.31 $1.82 Million - $2.52 Million	400,000 Added 36.36%	1,500,000 $7.44 Million
Q3 2022 Nov 14, 2022	SELL	$4.48 - $6.47 $448,000 - $647,000	-100,000 Reduced 8.33%	1,100,000 $6.53 Million
Q2 2022 Aug 12, 2022	SELL	$3.15 - $5.76 $708,750 - $1.3 Million	-225,000 Reduced 15.79%	1,200,000 $5.4 Million
Q1 2022 May 13, 2022	SELL	$4.26 - $7.48 $319,500 - $561,000	-75,000 Reduced 5.0%	1,425,000 $6.78 Million
Q4 2021 Feb 11, 2022	BUY	$4.75 - $7.5 $1.34 Million - $2.11 Million	281,150 Added 23.07%	1,500,000 $11.2 Million
Q2 2021 Aug 13, 2021	BUY	$5.79 - $8.6 $3.87 Million - $5.75 Million	668,850 Added 121.61%	1,218,850 $8.03 Million
Q1 2021 May 14, 2021	BUY	$6.5 - $10.53 $3.58 Million - $5.79 Million	550,000 New	550,000 $4.46 Million

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Rhenman & Partners Asset Management Ab, based on Form 13F filings with the SEC.

Stay updated on Rhenman & Partners Asset Management Ab with notifications on news.